PMV Pharma Closes $70 Million in Series D Financing

On August 3, 2020 PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, reported the completion of a $70 million Series D financing round. Avoro Capital, RA Capital Management and Wellington Management Company joined existing investors OrbiMed Advisors, Nextech Invest, Viking Global Investors, and Boxer Capital of Tavistock Group in the round (Press release, PMV Pharma, AUG 3, 2020, View Source [SID1234562779]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The proceeds will be used to advance PMV Pharma’s p53 product candidates. p53 is a tumor suppressor protein and the wild type, or normal, p53 protein plays a pivotal role in the body’s natural defense mechanism against cancer and induces a highly organized program of cellular death to prevent the proliferation of potentially cancerous cells.

Mutant p53 proteins can be misfolded and lose their wild type tumor suppressing function. p53 mutations are found in approximately half of all human cancers. PMV Pharma’s mechanism of action seeks to restore p53 to its normal, wild-type function, which could result in the selective killing of mutant cancer cells without affecting normal tissues.

"This financing provides PMV Pharma with the resources to expand our pipeline and to potentially advance multiple p53 therapies into the clinic," said David Mack, Ph.D., President and Chief Executive of PMV Pharma. "We are excited to have new and strong life science investors that include Avoro, RA Capital and Wellington join us in our pursuit of developing meaningful new medicines for cancer patients. The enthusiasm and confidence from our new and existing investors underscore the important advances we have made."

In addition, PMV Pharma announced the appointment of Rich Heyman, Ph.D. as Chair of the Board of Directors. An industry leader, entrepreneur and renowned scientist with a deep knowledge of and broad depth in the field of oncology, Dr. Heyman has more than 25 years of biopharma experience. He currently serves as Board Chair of ORIC Pharmaceuticals and is on the Board of Directors of Gritstone Oncology, Yumanity Therapeutics, Amunix Pharmaceuticals, Metacrine Inc., and Vividion Therapeutics.

Previously, Dr. Heyman was the co-founder and CEO of Aragon Pharmaceuticals and Seragon Pharmaceuticals, two biotech companies focused on discovering and developing therapeutics targeting hormone-dependent cancers. Johnson & Johnson purchased Aragon in 2013 and Genentech/Roche purchased Seragon in 2014.

"We are thrilled to have Rich join PMV Pharma’s Board of Directors as our Chair. His wealth of experience and proven track record of strategic business, scientific and clinical accomplishments will be invaluable as we continue to progress our pipeline of p53 programs towards the clinic," said Dr. Mack.

"PMV has made significant progress in designing small molecules that modulate p53 function, a well-known but previously inaccessible target in oncology," said Dr. Heyman. "The PMV team, its scientific founders and advisors have created potential therapies that could be first-in-class. I am excited to join as Chair of the Board and look forward to continuing to work with this talented team to help advance PMV’s p53 therapies."

ASLAN PHARMACEUTICALS APPOINTS KENNETH KOBAYASHI, MD, AS CHIEF MEDICAL OFFICER

On August 3, 2020 ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, reported that Dr Kenneth Kobayashi has been appointed Chief Medical Officer. Dr Kobayashi will be based in California and will be responsible for the global clinical development of ASLAN’s pipeline, including the lead program, ASLAN004, an antibody that blocks the IL-13 receptor, which is being developed for atopic dermatitis (AD) (Press release, ASLAN Pharmaceuticals, AUG 3, 2020, View Source [SID1234562680]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Kobayashi has more than 25 years of experience in drug development, clinical practice and regulatory affairs as a Dermatology expert. He most recently served as Senior Medical Director at Dermira, a subsidiary of Eli Lilly, where he was responsible for the development of lebrikizumab, a monoclonal antibody for atopic dermatitis, and supported five Phase 3 registration studies together with preclinical and early clinical development for two novel compounds.

Prior to joining Dermira, Dr Kobayashi was Clinical Development Medical Director at Novartis, in the Immunology, Hepatology and Dermatology Global Development Unit, where he supported the development programs for anti-IL-17C and anti-IgE monoclonal antibodies. He has also held senior and global leadership positions at LEO Pharma and was an Associate Professor, and Chair and Chief of the Division of Dermatology at the University of Ottawa and The Ottawa Hospital.

Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: "We are pleased to welcome Ken to our team and look forward to working with him as we plan for the late stage development of ASLAN004 in atopic dermatitis. He brings strong industry expertise and relationships from working on other novel biologics being developed for AD as well as his insights as a trained dermatologist. Ken’s appointment is an important step for ASLAN as we build our presence in the US in order to execute our global Phase 2b program in 2021."

Dr Ken Kobayashi, Chief Medical Officer, ASLAN Pharmaceuticals, commented: "I am very excited to join ASLAN and lead the global development of ASLAN004, a program I believe has the potential to be best-in-disease for atopic dermatitis and other indications. I am looking forward to working closely with the team as we prepare for important clinical data readouts later this year from the ongoing multiple ascending dose study in AD and plan our move into additional indications"

Dr Kobayashi completed his residency in Dermatology at the University of British Columbia and was a Chief Resident at the National Defence Medical Centre, Ottawa. He is an Adjunct Professor, Department of Medicine, at the University of Ottawa, and a fellow of the Royal College of Physicians and Surgeons of Canada and the American Academy of Dermatology.

IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020

On August 3, 2020 IMV Inc. ("IMV" or the "Corporation") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases including COVID-19, reported that it will hold a conference call and webcast on Wednesday, August 12, 2020 at 8:00 a.m. ET to discuss the company’s second quarter 2020 financial and operational results (Press release, IMV, AUG 3, 2020, View Source [SID1234562716]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Financial analysts are invited to join the conference call by dialing (866) 211-3204 (U.S. and Canada) or (647) 689-6600 (international) using the conference ID: 2593517.

Other interested parties will be able to access the live audio webcast at this link: View Source The webcast will be recorded and will then be available on the IMV website for 30 days following the call.

Syndax Announces Participation in BTIG Virtual Biotechnology Conference

On August 3, 2020 Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that members of its management team will participate virtually in the BTIG Biotechnology Conference on Monday, August 10, 2020 at 12:00 p.m. ET (Press release, Syndax, AUG 3, 2020, View Source [SID1234562681]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat can be accessed from the Investor section of the Company’s website at www.syndax.com, where a replay of the event will also be available for a limited time.

Selecta Biosciences Appoints Peter G. Traber, MD as Chief Medical Officer

On August 3, 2020 Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR, reported the appointment of Peter G. Traber, MD, to the position of Chief Medical Officer (Press release, Selecta Biosciences, AUG 3, 2020, View Source [SID1234562700]). Dr. Traber has been serving in the same position in an interim capacity, and joins the Company full-time, effective August 1, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Since becoming part of our organization, Peter has brought a wealth of expertise from his experience in large pharma, biotech, and academia that has substantially strengthened our clinical development capabilities, and we are extremely pleased that he will be joining us full-time as Chief Medical Officer," said Carsten Brunn, Ph.D., President and CEO of Selecta. "We’re confident that he will play a critical role in elevating the strength of our science and translating it clinically, as we explore new applications for ImmTOR in biologics, gene therapy, and immunotherapies for autoimmune diseases."

"I am proud to be part of an organization that is pioneering innovations that may advance the treatment of a number of challenging diseases with unmet needs," said Dr. Traber. "Selecta has the capabilities and scientific acumen to become the undisputed leader in targeted and specific immune tolerance, and I’m excited to help advance ImmTOR and explore its role in driving innovation that will ultimately help patients."

As Chief Medical Officer, Dr. Traber will oversee medical affairs, program management, and all aspects of clinical development and strategy, as well as provide scientific and clinical guidance for potential business development initiatives. He is the founder and president of PGT Life Sciences Consulting, a biopharmaceutical consultancy for which he provides drug development strategy, clinical trial design, and scientific oversight for a broad range of companies. In a previous role, Dr. Traber was the President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics. During his tenure, he successfully built a full drug development team and created the strategy to progress its lead compound forward in multiple indications, including a phase 3-ready program in NASH cirrhosis. Prior to Galectin, he served as the Chief Medical Officer and Senior Vice President, Clinical Development & Medical Affairs at GSK. Previously, he served as the President and CEO of the Baylor College of Medicine, and Chairman of Medicine and CEO of the University of Pennsylvania Health System. His experience also includes managing an academic research laboratory, serving on the editorial boards of medical journals, and he has authored more than 100 research articles, reviews, and book chapters. He received his medical degree from Wayne State University School of Medicine, holds a Bachelor of Science in Chemical Engineering from the University of Michigan, and earned a certificate in Medical Leadership from Wharton Business School. He is currently an Adjunct Professor of Medicine at the University of Pennsylvania and serves on the board of Caladrius Biosciences.